ストックスクリーナーアプリを入手
34.54
2.58%
0.87
前日終値:
$33.67
開ける：
$34.19
24時間の取引高:
4.89M
Relative Volume:
2.26
時価総額：
$5.90B
収益：
-
当期純損益:
$-354.30M
株価収益率:
-13.69
EPS:
-2.5234
ネットキャッシュフロー:
$-286.27M
1週間 パフォーマンス:
+5.89%
1か月 パフォーマンス:
+10.14%
6か月 パフォーマンス:
-8.87%
1年 パフォーマンス:
+377.07%
1日の値動き範囲:
$33.81
$34.99
1週間の範囲:
$32.33
$34.99
52週間の値動き範囲:
$6.92
$43.73
Cogent Biosciences Inc Stock (COGT) Company Profile
Compare COGT vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
34.54 | 5.90B | 0 | -354.30M | -286.27M | -2.5234 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | 再開されました | Jefferies | Buy |
| 2025-11-10 | アップグレード | Stifel | Hold → Buy |
| 2025-11-10 | アップグレード | Wedbush | Neutral → Outperform |
| 2025-10-16 | 開始されました | Stifel | Hold |
| 2025-09-03 | 開始されました | Raymond James | Strong Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-11 | ダウングレード | Needham | Buy → Hold |
| 2024-02-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | 開始されました | Citigroup | Buy |
| 2023-12-11 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-12-08 | 開始されました | JP Morgan | Overweight |
| 2023-04-28 | 開始されました | Robert W. Baird | Outperform |
| 2023-03-27 | 再開されました | H.C. Wainwright | Buy |
| 2022-12-14 | 開始されました | Needham | Buy |
| 2022-06-28 | 開始されました | Guggenheim | Buy |
| 2021-10-11 | 開始されました | H.C. Wainwright | Buy |
| 2021-06-09 | 再開されました | Jefferies | Buy |
| 2020-12-23 | 開始されました | Piper Sandler | Overweight |
| 2020-10-14 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Cogent Biosciences Inc (COGT) 最新ニュース
Trading Systems Reacting to (COGT) Volatility - Stock Traders Daily
Cogent Biosciences Inc (COGT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cogent Biosciences Inc (COGT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cogent Biosciences Inc (COGT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cogent Biosciences Inc (COGT) Institutional Confidence - TradingKey
Cogent Biosciences Inc (COGT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cogent Biosciences Inc (COGT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cogent Biosciences Inc (COGT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cogent Biosciences Inc (COGT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Stifel reiterates Cogent stock Buy rating after trial data - Investing.com UK
Stifel reiterates Cogent stock Buy rating after trial data By Investing.com - Investing.com India
Cogent Biosciences Inc (COGT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage (NASDAQ:COGT) - Seeking Alpha
Cogent Biosciences (COGT) Is Up 6.7% After Positive PEAK Trial Data and FDA Priority ReviewWhat's Changed - Sahm
Cogent Biosciences, Inc. (COGT) Presents at European Hematology Association (EHA) 2026 CongressSlideshow - Seeking Alpha
Cogent Biosciences' Potential Rare Blood Disease Treatment Meets Endpoints in Clinical Trial - Moomoo
Cogent Gallops on Data Release - Baystreet.ca
Cogent Biosciences unveils pivotal APEX trial data at EHA 2026 - grafa.com
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association Congress - Investing News Network
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association Congress - Investing News Network
Cogent unveils positive preclinical data for JAK2 inhibitor CGT1145 - grafa.com
Cogent Biosciences Announces Preclinical Data from Novel - GlobeNewswire
Cogent Biosciences Announces Detailed Data from Apex Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis - marketscreener.com
Director for Cogent Biosciences (NASDAQ: COGT) granted 17,901 stock options - Stock Titan
Cogent Biosciences (COGT) director receives 17,901 stock options at $31.98 strike - Stock Titan
Cogent Biosciences (COGT) director linked to option grant for funds - Stock Titan
Director at Cogent Biosciences (NASDAQ: COGT) receives 17,901 stock options - Stock Titan
Cogent Biosciences (COGT) director Arlene Morris receives grant of 17,901 stock options - Stock Titan
Cogent Biosciences (NASDAQ: COGT) 2026 meeting backs board, auditor and pay - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
How Investors May Respond To Cogent Biosciences (COGT) Priority Review For Bezuclastinib GIST Regimen - Yahoo Finance
Cogent Biosciences Inc Annual Shareholders Meeting Transcript - GuruFocus
Is Cogent Biosciences, Inc. (COGT) A Good Stock To Buy Now? - Insider Monkey
Cogent Biosciences (COGT) Is Down 7.3% After Priority Review Win For Bezuclastinib Combo In GISTHas The Bull Case Changed? - Sahm
COGT News | COGENT BIOSCIENCES INC (NASDAQ:COGT) - ChartMill
Analysts Are Bullish on Top Healthcare Stocks: Agios Pharma (AGIO), Cogent Biosciences (COGT) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (SMMT), Oculis Holding (OCS) and Cogent Biosciences (COGT) - The Globe and Mail
Assessing Cogent Biosciences (COGT) Valuation After PEAK Phase 3 Success And FDA Priority Review - Sahm
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT) and Medline (MDLN) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Nuvalent (NUVL), Cogent Biosciences (COGT) and Anteris Technologies Global Corp. (AVR) - The Globe and Mail
COGT Technical Analysis & Stock Price Forecast - Intellectia AI
Stifel reiterates Cogent stock Buy rating on GIST drug data - Investing.com UK
Stifel Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Stifel reiterates Cogent stock Buy rating on GIST drug data By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Cogent stock rating on trial results By Investing.com - Investing.com Australia
Cogent Biosciences Stock Surges 136%. Investors See Promise in Its Cancer Drug. - MSN
UBS Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Cogent Biosciences (COGT) Reveals Promising Phase 3 Trial Results for Bezuclastinib - GuruFocus
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors at 2026 American Society of Clinical Oncology Annual Meeting - Investing News Network
Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Cogent Biosciences (COGT) and GlaxoSmithKline (GSK) - The Globe and Mail
Cogent Biosciences presented detailed clinical data from its PEAK Phase III trial at the 2026 American Society of Clinical Oncology Annual Meeting. - Bitget
Cogent Biosciences Inc (COGT) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):